NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

KRAS抑制劑 - 市場機會,流行病學、市場預測,開發平台,競爭分析:2020年∼2030年

KRAS Inhibitors - Market Opportunity, Epidemiology & Market Forecast, Pipeline and Competitive Analysis, 2020-2030

出版商 Mellalta Meets LLP 商品編碼 945512
出版日期 內容資訊 英文 2 PDFs: 121 Pages + 30 Pages
訂單完成後即時交付
價格
KRAS抑制劑 - 市場機會,流行病學、市場預測,開發平台,競爭分析:2020年∼2030年 KRAS Inhibitors - Market Opportunity, Epidemiology & Market Forecast, Pipeline and Competitive Analysis, 2020-2030
出版日期: 2020年06月30日內容資訊: 英文 2 PDFs: 121 Pages + 30 Pages
簡介

KRAS突變可直接影響癌症患者的醫療決策。KRAS變異,在癌症的最大25%中存在,不過,致癌性變異體在許多癌症有不同的盛行率。

本報告提供KRAS抑制劑市場相關調查分析,市場機會,流行病學、市場預測,開發平台,競爭分析相關的系統性資訊。

對象企業

  • 1. Silenseed
  • 2. Amgen
  • 3. Gilead
  • 4. Mirati Therapeutics
  • 5. Johnson & Johnson
  • 6. Merck, Moderna Therapeutics
  • 7. Oblique Therapeutics
  • 8. Johnson & Johnson
  • 9. Aurigene
  • 10. Cotinga Pharmaceuticals
  • 11. Codiak Biosciences
  • 12. Mirati Therapeutics
  • 13. Revolution Medicines
  • 14. Boehringer Ingelheim
  • 15. Bayer
  • 16. Sanofi/X-Chem
  • 17. X-Chem
  • 18. BridgeBio Pharma
  • 19. 其他

目錄

第1章 概要

第2章 要點

第3章 KRAS標的背景

第4章 適應的優先順序

  • 癌症的KRAS變異型

第5章 KRAS癌症的流行病學

  • 美國、EU的KRAS變異癌症的發生率
  • KRAS G12C、KRAS G12D的頻率:各腫瘤類型

第6章 KRAS的授權和合作交易

  • KRAS的授權詳細內容與交易額
  • KRAS的收購詳細內容與交易額

第7章 KRAS的開發平台形勢

  • KRAS的開發平台分析
  • KRAS的臨床試驗形勢

第8章 KRAS的開發平台藥物的簡介與臨床試驗分析

  • Amgen:AMG
    • 產品簡介、說明
    • 臨床試驗
    • 聯盟
    • 其他開發
  • Mirati:MRTX
    • 產品簡介、說明
    • 臨床試驗
    • 聯盟
    • 其他開發
  • Boehringer Ingelheim:BI 1701963
    • 產品簡介、說明
    • 臨床試驗
    • 聯盟
    • 其他開發等

第9章 市場預測

  • Amgen510銷售潛在力
  • 商機

第10章 KRAS相關KOL的見解

第11章 今後的活動

第12章 附錄

目錄
Product Code: MM202002

This KRAS report covers the KRAS market opportunity providing key competitive analysis, 37 companies with pipeline drug profiles, clinical trials, upcoming events, other Developments (Collaborations Details, Funding, etc.), Epidemiology forecast of Cancers with KRAS mutation and % of mutation frequency, licensing and deals, as well as presenting market forecast from 2019 to 2030.

Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation may directly influence medical decisions in patients with carcinomas as demonstrated by the recent research. Despite its discovery over three decades ago, it's remained elusive as a drug target, although several downstream mediators are effectively drugged. KRAS itself is described collectively of the master switches for cancer and is especially associated as a driver for Colorectal Carcinoma (CRC), Non-small Lung cancer (NSCLC), and carcinoma.

While KRAS mutations are present in up to 25% of cancers, the oncogenic variants have different prevalence rates in numerous cancers. As per the American Cancer Society, around 200,000 patients are diagnosed every year with lung adenocarcinomas. That puts the KRAS-G12C population within the USA at 14,000-28,000 patients annually. within the case of KRAS-G12C-positive colorectal cancer (CRC), closer to 3000 patients are diagnosed every year.

Amgen certainly has a headstart over its potential opponents, and it is unlikely that a competitor would have the option to sling in front of an expedited development program for AMG 510. Mirati Therapeutics, another competitor, entered the clinic with the KRAS-G12C inhibitor MRTX849, followed by other companies. While there is already a lot of excitement about the new drug, the number of patients who have been treated with it is relatively small.

This KRAS report covers the KRAS market opportunity providing key competitive analysis, 20+ company with pipeline drug profiles, clinical trials, upcoming events, other Developments (Collaborations Details, Funding, etc.), Epidemiology forecast of Cancers with KRAS mutation and % of mutation frequency, licensing and deals, as well as presenting market forecast from 2019 to 2030.

Key Takeaways from the Report:

  • Indication Prioritization: KRAS Mutation patterns in cancers
  • KRAS Mutated Cancers Epidemiology Forecast from 2019-2030
  • Business Transactions & Strategies: Key collaborations and deal values
  • Pipeline Development: Product Profiles, Clinical Trials & Results
  • Market Forecast of KRAS Inhibitors from 2019-2030
  • Recent & Upcoming events

Comapnies covered:

  • 1. Silenseed
  • 2. Amgen
  • 3. Gilead
  • 4. Mirati Therapeutics
  • 5. Johnson & Johnson
  • 6. Merck, Moderna Therapeutics
  • 7. Oblique Therapeutics
  • 8. Johnson & Johnson
  • 9. Aurigene
  • 10. Cotinga Pharmaceuticals
  • 11. Codiak Biosciences
  • 12. Mirati Therapeutics
  • 13. Revolution Medicines
  • 14. Boehringer Ingelheim
  • 15. Bayer
  • 16. Sanofi/X-Chem
  • 17. X-Chem
  • 18. BridgeBio Pharma
  • 19. Others

TABLE OF CONTENTS

1. OVERVIEW

2. KEY TAKEAWAYS

3. The KRAS Target BACKGROUND

4. Indication Prioritization

  • KRAS Mutation patterns in cancers

5. KRAS CANCERS EPIDEMIOLOGY

  • Incidence for KRAS Mutated Cancers in the US and EU
  • Frequency of KRAS G12C & KRAS G12D by Tumour Type

6. KRAS LICENSING AND COLLABORATION DEALS

  • KRAS Licensing Details and Deal values
  • KRAS Acquisition Details & Deal Values

7. KRAS PIPELINE LANDSCAPE

  • KRAS Pipeline Analysis
  • KRAS Clinical Trial Landscape

8. KRAS PIPELINE DRUG PROFILES & CLINICAL TRIAL ANALYSIS

  • Amgen: AMG 510
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Mirati: MRTX 849
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • Boehringer Ingelheim: BI 1701963
    • Product Profile & Description
    • Clinical Trials
    • Collaborations
    • Other Developments
  • List of drugs continued...

9. Market Forecast

  • Amgen 510 Sales Potential
  • Revenue Opportunity

10. KOL VIEWS ON KRAS

11. UPCOMING EVENTS

12. Appendix

List of Tables

  • 1. KRAS Oncogenic mutations frequency in human cancers, 2020
  • 2. Global Incidence cases of KRAS mutated Cancers Overview, 2020
  • 3. Incidence cases of NSCLC adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 4. Incidence cases of Colorectal adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 5. Incidence cases of Pancreatic adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 6. Incidence cases of Endometrial adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 7. KRAS Licensing Details and Deal values, 2020
  • 8. KRAS Acquisition Details & Deal Values, 2020
  • 9. Total Products for KRAS Inhibitors by Phase, 2020
  • 10. Total Products for KRAS Inhibitors in Clinical Trials, 2020
  • 11. Amgen 510 Sales Potential by Cancers, 2020-2030
  • 12. Revenue Potential for KRAS inhibitors
  • 13. Upcoming Events for KRAS, 2020

List of Figures

  • 1. The KRAS cycle
  • 2. KRAS Oncogenic mutations frequency in human cancers, 2020
  • 3. Global Incidence cases of KRAS mutated Cancers Overview, 2020
  • 4. Incidence cases of NSCLC adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 5. Incidence cases of Colorectal adenocarcinoma & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 6. Incidence cases of Pancreatic adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 7. Incidence cases of Endometrial adenocarcinoma, & Frequency of KRAS G12C & KRAS G12D, 2020-2030
  • 8. KRAS Licensing Details and Deal values, 2020
  • 9. KRAS Acquisition Details & Deal Values, 2020
  • 10. Total Products for KRAS Inhibitors by Phase, 2020
  • 11. Total Products for KRAS Inhibitors in Clinical Trials, 2020
  • 12. Amgen 510 Sales Potential by Cancers, 2020-2030
  • 13. Revenue Potential for KRAS inhibitors
  • 14. Upcoming Events for KRAS, 2020